A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report
Case report published in Hematology (2022)
Abstract
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction associated with thrombosis. Clinical scoring systems and the presence of anti-platelet factor 4 (anti-PF4)/heparin antibodies determine the diagnosis. CASE PRESENTATION: A 57-year-old man who was treated with acenocoumarol due to a chronic left ventricular thrombus was admitted to the hospital for severe SARS-CoV-2 pneumonia and pulmonary embolism. The patient was started on bemiparin and discharged. Left lower limb acute arterial ischemia and thrombocytopenia were diagnosed 18 days later. Computed tomography angiography revealed a large left ventricular thrombus and multiple arterial thrombi. Left femoral-popliteal thromboembolectomy was performed. Anti-PF4/heparin antibodies confirmed an HIT diagnosis. Fondaparinux (7.5 mg/24 h) was initiated, but cardiac surgery was necessary. Bivalirudin was used during surgery, with an initial load (1.25 mg/kg) and maintenance infusion (2.5 mg/kg/h). The cardiac thrombus was extracted, but the patient experienced a postsurgical myocardial infarction. Percutaneous cardiovascular intervention (PCI) required a bivalirudin load (0.75 mg/kg) and maintenance infusion (1.75 mg/kg/h). No coronary lesions were detected, and argatroban was started afterwards (0.5 µg/kg/min). When the platelet count exceeded 100 × 109/L, acenocoumarol was initiated. Thereupon, acetylsalicylic acid (100 mg/24 h) was added. No other complications have been reported to date. CONCLUSION: The clinical presentation of intraventricular and multiple arterial thrombi is remarkable. SARS-CoV-2 infection likely contributed to a hypercoagulable state. The management of patients with HIT undergoing cardiac surgery is challenging. If surgery cannot be delayed, then treatment with bivalirudin is recommended. Additionally, this drug is recommended for PCI. Bivalirudin is safe and well-tolerated in both procedures.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Резюме
Detailed case of post-COVID-19 HIT with intraventricular and multiple arterial thrombi treated successfully with bivalirudin during cardiac surgery and PCI, then argatroban bridge — illustrates the role of hirudin-class anticoagulation in COVID-era hypercoagulability.
Почему это важно для гирудотерапии
В данном описании клинического случая рассказывается о 57-летнем мужчине с хроническим тромбом левого желудочка, у которого на фоне тяжелой пневмонии COVID-19 развилась гепарин-индуцированная тромбоцитопения (HIT). Пациенту были проведены кардиохирургическая операция и чрескожное вмешательство с использованием бивалирудина, а затем аргатробана, с последующим переходом на аценокумарол и ацетилсалициловую кислоту. Авторы заключают, что бивалирудин рекомендован пациентам с HIT, которым требуются кардиохирургические операции или PCI, и, по-видимому, является безопасным и хорошо переносимым. В аннотации не упоминаются лепирудин, гирудин, терапия пиявками или какие-либо производные пиявок препараты. Для ASH связь с гирудотерапией или секретомом пиявок отсутствует; данный случай описывает альтернативную антикоагулянтную терапию без какого-либо использования связанных с пиявками методов лечения.
Цитирование
A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report.
Lazaro-Garcia A et al. · Hematology, 2022
Связанный клинический контекст
Узнайте, как это исследование связано с клинической практикой
Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: 18 июня 2026 г.